Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Penyakit Dalam Indonesia Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education and Research Institute
Sari, Sakinah Rahma
Unknown Affiliation
Health Professions Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Abnormal Liver Function in Predicting COVID-19 Patients’ Prognosis Sari, Sakinah Rahma; Kurniawan, Juferdy
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Despite of the high prevalence of liver enzyme elevation in COVID-19 patients, its effect on predicting COVID-19 patients’ prognosis was still debatable. This evidence-based case report aims to evaluate the effect of abnormal liver function in the prognosis of COVID-19 patients. Literature searching was performed on August 16-17 2021 using 3 databases: PubMed, Scopus, and Proquest. The articles selected by title/abstract screening, duplication elimination, and applying eligibility criteria were then appraised using Centre of Evidence Based Medicine (CEBM), University of Oxford. Some of the studies reported there were no significant difference in the prognosis of COVID-19 patient with and without abnormal liver function. However, most of the studies reported abnormal liver function as an independent poor prognosis predictor in COVID-19 patients. Based on the study with the highest level of evidence, the elevation of AST and ALT increase the risk of poor prognosis in COVID-19 patients [OR 2.98 (95% CI 2.35-3.77), p<0.0001) and OR 1.73 (95% CI 1.32-2.27, p<0.001)]. Based on the 34 studies appraised, we conclude that abnormal liver function will increase the risk of poor prognosis in COVID-19 patients. Thus, careful monitoring must be done in COVID-19 patients with abnormal liver function.
Nimotuzumab in Combination with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma Cancer Patients: A Single-Arm Observational Study Sari, Sakinah Rahma; Rachman, Andhika
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 8 No. - (2024): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v8i-.244

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) incidence is predicted to increase in 2030. Most patients with HNSCC are diagnosed as locally advanced (LA), with a worse prognosis even with combination therapy. Nimotuzumab, a humanized-antibody monoclonal against epidermal growth factor receptor (EGFR), was hypothesized to improve LA-HNSCC patients’ survival. This study evaluated the real-world efficacy of adding nimotuzumab to chemoradiation (CRT) in patients with LA-HNSCC survival. Methods:This single-arm retrospective study was conducted in Dr. Cipto Mangunkusumo General Hospital. Patients diagnosed with LA-HNSCC from October 21, 2009, to May 21, 2024 were included. The outcomes assessed were patients’ two-year overall survival (OS), two-year progression-free survival (PFS), and treatment toxicities. Results: From the total of 30 patients included in the analysis, 93.3% were alive, and 86.7% of patients survived disease progression at the end of the two-year observation. The most common side effects were toxicities against the salivary gland (32.7%), mucous lining (21.2%), and skin (30.8%). Conclusions:This single-arm real-world study demonstrated the exceptional efficacy and safety of nimotuzumab in combination with CRT.
Co-Authors Andhika Rachman Juferdy Kurniawan